How are partnerships between pharma firms and biotech firms likely to evolve over the coming months? What different types of options are for small and medium–sized biotech enterprises to take forward promising development programs? What new models for financing drug development are emerging in the US? What are the pros and cons of each model for biotech ventures? And how can these models be applied in Germany, Europe and further afield?

Take the opportunity to discuss these issues and more first hand as Nature Biotechnology puts seasoned pharma and biotech management together with experienced investors at BIO–Europe in Hamburg.

This Bioentrepreneur Roundtable will take place the day before the BIO–Europe Conference on Sunday 11 November from 15:30 at the Grand Elysee Hotel, Hamburg, Germany followed by networking drinks and snacks. There is no charge to attend the Bioentrepreneur Roundtable. The maximum number of registrants is 140, allocated on a first come first serve basis.

For more information or to register, please send full company name and contact details to germanyroundtable@nature.com

For more information on the BIO–Europe Conference, please visit www.ebdgroup.com/bioeurope